ResearcherShanxi Medical UniversityActive in the last 2 years

Chaojie Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-0137-4704; OpenAlex author ID A5103856151. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 3

KRT13 Drives Pancreatic Cancer Malignancy Via the PI3K/AKT-PPARG Axis While Enhancing Sensitivity to Navitoclax. Co-author DOI 10.12659/msm.952797 ↗
DUPAN-2 in pancreatic cancer: Systematic review and meta-analysis. Last author DOI 10.1016/j.cca.2024.120080 ↗
PDO-Based Drug Screening in Advanced Pancreatic Cancer Co-author DOI 10.1053/j.gastro.2024.10.045 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zhigang Wei · 2 shared papers, 2024–2025 · strength 0.64
- Paper PDO-Based Drug Screening in Advanced Pancreatic Cancer DOI 10.1053/j.gastro.2024.10.045 ↗
- Paper DUPAN-2 in pancreatic cancer: Systematic review and meta-analysis. DOI 10.1016/j.cca.2024.120080 ↗
Yongping Cui · 1 shared paper, 2026 · strength 0.30
- Paper KRT13 Drives Pancreatic Cancer Malignancy Via the PI3K/AKT-PPARG Axis While Enhancing Sensitivity to Navitoclax. DOI 10.12659/msm.952797 ↗
Zhigang Wei · 1 shared paper, 2026 · strength 0.30
- Paper KRT13 Drives Pancreatic Cancer Malignancy Via the PI3K/AKT-PPARG Axis While Enhancing Sensitivity to Navitoclax. DOI 10.12659/msm.952797 ↗
Xiaowen Gong · 1 shared paper, 2025 · strength 0.28
- Paper DUPAN-2 in pancreatic cancer: Systematic review and meta-analysis. DOI 10.1016/j.cca.2024.120080 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.